FDA 483 - Biospace Inc. - April 22, 2019

An FDA inspection of Biospace Inc., a medical device manufacturer in Los Angeles, CA, revealed two significant observations. The firm failed to document acceptance activities, specifically quality inspections of received devices. Additionally, Biospace Inc. had not established its own procedures for corrective and preventive actions (CAPA).